

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Datang International Power Generation Co., Ltd..



大唐国际发电股份有限公司

DATANG INTERNATIONAL POWER GENERATION CO., LTD.

(a sino-foreign joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 00991)

ANNOUNCEMENT

UPDATE IN RESPECT OF THE H-SHARE ISSUANCE

Reference is made to (i) the whitewash circular dated 9 February 2017 (the “**Whitewash Circular**”) in respect of, among other things, the A-Share Issuance, the H-Share Issuance and the Whitewash Waiver published by Datang International Power Generation Co., Ltd. (the “**Company**”); (ii) the whitewash supplemental circular dated 13 March 2017 (the “**Whitewash Supplemental Circular**”) in respect of the Whitewash Circular published by the Company; (iii) the poll results announcement of the Company dated 31 March 2017 in respect of the poll results of the EGM and the Class Meetings to approve the Whitewash Transactions; (iv) the announcement of the Company dated 31 March 2017 in respect of the adjustment to the H-Share Issue Price (the “**H-Share Issue Price Adjustment Announcement**”); (v) the announcement of the Company dated 17 April 2017 in respect of the acceptance by CSRC of the application for the H-Share Issuance by the Company; (vi) the announcement of the Company dated 20 April 2017 in respect of the acceptance by CSRC of the application for the A-Share Issuance by the Company; (vii) the announcement of the Company dated 24 May 2017 in respect of the receipt of feedback on the A-Share Issuance issued by the CSRC; (viii) the announcement of the Company dated 15 June 2017 in relation to the reply made in respect of CSRC’s feedback on the A-Share Issuance; (ix) the announcement of the Company dated 20 September 2017 in respect of the adjustments to the A-Share Issuance; (x) the announcement of the Company dated 20 September 2017 in relation to the reply made in respect of CSRC’s feedback on A-Share Issuance; (xi) the announcement of the Company dated 21 September 2017 in respect of the receipt of CSRC Approval for the H-Share Issuance; (xii) the announcement of the Company dated 30 October 2017 in relation to the reply made in respect of the questions in the notification letter on A-Share Issuance; and (xiii) the announcement of the Company dated 31 October 2017 in relation to the approval by the issuance committee of CSRC in respect of the application for the A-Share Issuance.

Unless otherwise defined, terms undefined herein shall have the meanings ascribed to them in the Whitewash Circular and/or the Whitewash Supplemental Circular.

As disclosed in the Whitewash Circular and/or the Whitewash Supplemental Circular, the H-Share Subscription Shares shall be subscribed by the H-Share Subscription Shares Subscriber and save for the lock-up period in respect of the H-Share Issuance disclosed in the Whitewash Circular, the H-Share Subscription Shares which the H-Share Subscription Shares Subscriber will be acquiring pursuant to the H-Share Issuance will not be transferred, charged or pledged to any other person. Following the upward adjustment to the H-Share Issue Price as disclosed in the H-Share Issue Price Adjustment Announcement, the aggregate proceeds from the issue of 2,794,943,820 H-Share Subscription Shares at HK\$2.226 per H-Share Subscription Share proposed to be raised from the H-Share Issuance amounts to approximately HK\$6,221.5 million (the “**H-Share Issuance Proceeds**”).

The Company has been notified by CDC that in connection with the H-Share Issuance, the H-Share Subscription Shares Subscriber shall be CDOHKC. Further, CDOHKC (as borrower) has, on 11 February 2018, entered into a facility agreement with Wing Lung Bank, Limited (“**WLB**”) (as mandated lead arranger and bookrunner, facility agent and security agent) in connection with a term loan facility of HK\$5,300 million (the “**Facility**”) which shall be applied by CDOHKC for the payment of part of the H-Share Issuance Proceeds. The balance of the H-Share Issuance Proceeds shall be funded by the internal resources of CDC. The Facility is for a term of 36 months after the initial utilisation date.

As a condition precedent to the utilisation of the Facility by CDOHKC, CDOHKC (as chargor) entered into a Charge over Shares (the “**Share Charge**”) with WLB (as security agent) on 11 February 2018. Pursuant to the terms of the Share Charge, all the 480,680,000 H-Shares held in the name of CDOHKC and the 2,794,943,820 H-Share Subscription Shares to be subscribed by CDOHKC shall be pledged to WLB. Pursuant to the terms and conditions of the Share Charge, in the event of default by CDOHKC, WLB shall be entitled to enforce the Share Charge which may result in a transfer of voting rights in respect of such pledged securities.

The Company will make further announcements in respect of the progress of the A-Share Issuance and the H-Share Issuance in accordance with the requirements of the Listing Rules and other applicable requirements in the PRC as and when appropriate.

WARNING: THE COMPLETION OF THE WHITEWASH TRANSACTIONS IS SUBJECT TO THE SATISFACTION OF OTHER CONDITIONS, INCLUDING THE OBTAINING OF THE CSRC APPROVAL IN RESPECT OF THE A-SHARE ISSUANCE. ACCORDINGLY, THE WHITEWASH TRANSACTIONS MAY OR MAY NOT PROCEED. SHAREHOLDERS AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES, AND ARE RECOMMENDED TO CONSULT THEIR STOCKBROKER, BANK MANAGER, SOLICITOR OR OTHER PROFESSIONAL ADVISER IF THEY ARE IN ANY DOUBT ABOUT THEIR POSITION AND AS TO ACTIONS THEY SHOULD TAKE.

By Order of the Board
Ying Xuejun
Company Secretary

Beijing, the PRC, 12 February 2018

As at the date of the announcement, the Board comprises (a) two executive Directors, namely Wang Xin and Ying Xuejun; (b) eight non-executive Directors, namely Chen Jinhang, Liu Chuandong, Liang Yongpan, Zhu Shaowen, Cao Xin, Zhao Xianguo, Liu Haixia and Guan Tiangang (Mdm.); and (c) five independent non-executive Directors, namely Liu Jizhen, Feng Genfu, Luo Zhongwei, Liu Huangsong and Jiang Fuxiu.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statements in this announcement misleading.

As at the date of this announcement, the directors of CDC comprises Chen Jinhang, Chen Feihu, Sun Hanhong, Sun Xinguo, Chen Qiliang, Xia Donglin and Wang Wanchun.

The directors of CDC jointly and severally accept full responsibility for the accuracy of the information contained in this announcement relating to CDC and parties acting in concert with it, and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statements in this announcement misleading.